HBsAg seropositive status and survival after renal transplantation: Meta-analysis of observational studies

被引:109
作者
Fabrizi, F [1 ]
Martin, P
Dixit, V
Kanwal, F
Dulai, G
机构
[1] Maggiore Hosp, Div Nephrol & Dialysis, IRCCS, Milan, Italy
[2] Mt Sinai Sch Med, Div Liver Dis, New York, NY 10029 USA
[3] Univ Calif Los Angeles, Sch Med, Div Digest Dis, Los Angeles, CA USA
[4] GLAVA Healthcare Syst, Los Angeles, CA USA
关键词
hepatitis B virus (HBV); HBV surface antigen (HBsAg); meta-analysis; mortality; observational studies; renal transplantation (RT);
D O I
10.1111/j.1600-6143.2005.01113.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
The natural history of hepatitis B virus (HBV) infection after renal transplantation (RT) remains unclear. We conducted a systematic review of the published medical literature on the impact of HBV surface antigen (HBsAg) seropositivity on survival of RT recipients. We used the random effects model of DerSimonian and Laird to generate a summary estimate of the relative risk for mortality and graft loss in HBsAg positive RT recipients across the published studies. We identified six observational studies (6050 unique patients); all of them being cohort, retrospective studies. Pooling of study results demonstrated that HBsAg in serum was an independent and significant risk factor for death after RT; the summary estimate for relative risk was 2.49 with a 95% confidence interval (95% CI) of 1.64-3.78. A test for homogeneity of the relative risk across the studies gave a p-value of < 0.0001. HBsAg seropositivity was an independent and significant risk factor for graft failure after RT; the summary estimate was 1.44 with a 95% CI of 1.02-2.04 (homogeneity test, p < 0.0001). This meta-analysis shows that HBsAg positive RT recipients have an increased risk for mortality and graft failure compared to seronegative patients.
引用
收藏
页码:2913 / 2921
页数:9
相关论文
共 45 条
[1]   Causes of death and mortality risk factors [J].
Alonso, A ;
Oliver, J .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 :8-10
[2]  
[Anonymous], HDB KIDNEY TRANSPLAN
[3]   Natural history of hepatitis B and C in renal allograft recipients [J].
Aroldi, A ;
Lampertico, P ;
Montagnino, G ;
Passerini, P ;
Villa, M ;
Campise, MR ;
Lunghi, G ;
Tarantino, A ;
Cesana, BM ;
Messa, P ;
Ponticelli, C .
TRANSPLANTATION, 2005, 79 (09) :1132-1136
[4]   EFFECT OF HEPATITIS-B ANTIGENEMIA ON LONG-TERM SUCCESS AND HEPATIC DISEASE IN RENAL-TRANSPLANT RECIPIENTS [J].
BERNE, TV ;
FITZGIBBONS, TJ ;
SILBERMAN, H .
TRANSPLANTATION, 1977, 24 (06) :412-415
[5]   Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation [J].
Breitenfeldt, MK ;
Rasenack, J ;
Berthold, H ;
Olschewski, M ;
Schroff, J ;
Strey, C ;
Grotz, WH .
CLINICAL TRANSPLANTATION, 2002, 16 (02) :130-136
[6]   Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS [J].
Burdick, RA ;
Bragg-Gresham, JL ;
Woods, JD ;
Hedderwick, SA ;
Kurokawa, K ;
Combe, C ;
Saito, A ;
LaBrecque, J ;
Port, FK ;
Young, EW .
KIDNEY INTERNATIONAL, 2003, 63 (06) :2222-2229
[7]  
CHAN JB, 1996, TRANSPLANT P, V28, P1490
[8]   THE IMPACT OF DONOR AND RECIPIENT HEPATITIS-B SURFACE-ANTIGEN STATUS ON LIVER-DISEASE AND SURVIVAL IN RENAL-TRANSPLANT RECIPIENTS [J].
CHAN, PCK ;
LOK, ASF ;
CHENG, IKP ;
CHAN, MK .
TRANSPLANTATION, 1992, 53 (01) :128-131
[9]   Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients [J].
Chan, TM ;
Fang, GX ;
Tang, CSO ;
Cheng, IKP ;
Lai, KN ;
Ho, SKN .
HEPATOLOGY, 2002, 36 (05) :1246-1252
[10]  
Corrêa José Roberto Missel, 2003, Rev. Assoc. Med. Bras., V49, P389, DOI 10.1590/S0104-42302003000400029